Pages that link to "Q89564940"
Jump to navigation
Jump to search
The following pages link to Marina Konopleva (Q89564940):
Displaying 50 items.
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia (Q24313505) (← links)
- Advances in understanding the leukaemia microenvironment (Q26995023) (← links)
- Role of Microenvironment in Resistance to Therapy in AML (Q27027502) (← links)
- Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia (Q27851423) (← links)
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs (Q28548058) (← links)
- Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104 (Q28741513) (← links)
- Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment (Q30514797) (← links)
- Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors (Q33234337) (← links)
- Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma (Q33288957) (← links)
- Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase (Q33387519) (← links)
- CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia (Q33410331) (← links)
- Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients (Q33415505) (← links)
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia (Q33420436) (← links)
- Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction (Q33561797) (← links)
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor (Q33597663) (← links)
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia (Q33702409) (← links)
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia (Q33702412) (← links)
- Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. (Q33732534) (← links)
- Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia (Q33764269) (← links)
- Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib (Q33772438) (← links)
- Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1 (Q33798463) (← links)
- Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK (Q33810952) (← links)
- Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells (Q33875609) (← links)
- AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth (Q33877778) (← links)
- Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations (Q33929924) (← links)
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia (Q33949752) (← links)
- Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations (Q34011740) (← links)
- Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a (Q34051649) (← links)
- Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia (Q34095013) (← links)
- SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia (Q34098428) (← links)
- Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment (Q34115953) (← links)
- The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells (Q34194198) (← links)
- A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas (Q34277465) (← links)
- Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles (Q34312462) (← links)
- Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia (Q34314927) (← links)
- Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model (Q34343680) (← links)
- Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia (Q34392488) (← links)
- Targeting hypoxia in the leukemia microenvironment (Q34401785) (← links)
- The Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic-acid Methyl Ester Has Potent Anti-diabetic Effects in Diet-induced Diabetic Mice and Lepr Mice (Q34412580) (← links)
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias (Q34451540) (← links)
- Modest activity of pomalidomide in patients with myelofibrosis and significant anemia (Q34512203) (← links)
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). (Q34550540) (← links)
- The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo (Q34618835) (← links)
- Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies (Q34664579) (← links)
- Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). (Q34775350) (← links)
- TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment (Q34795604) (← links)
- Antidiabetic therapies affect risk of pancreatic cancer (Q34976430) (← links)
- A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults (Q35004970) (← links)
- Mechanisms of drug resistance in AML. (Q35025447) (← links)
- Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. (Q35060682) (← links)